Clinical Study

Endovascular Treatment for Acute Thromboembolic Occlusion of the Superior Mesenteric Artery and the Outcome Comparison between Endovascular and Open Surgical Treatments: A Retrospective Study

Table 2

Basic characteristics and perioperative biochemical parameters between endovascular and open surgical treatment groups.

VariableAll patientsEndovascular groupOpen surgery
()()group ()

Age (year)0.321.01
Male (%/)63.3 (20)66.7 (12)58.30 (7)0.71
Etiology (%/)<0.05
 Embolic70% (21)83.3% (15)50% (6)
 Thrombotic30% (9)16.7% (3)50% (6)
Comorbidity (%/)
 Hypertension50% (15)33.3% (6)75% (9)0.06
 Diabetes mellitus13.3% (4)11.1% (2)16.6% (2)0.68
 Chronic renal failure6.7% (2)11.1% (2)00.5
 Peripheral arterial disease20% (6)16.7% (3)25% (3)0.66
 Atrial fibrillation53.33% (16)50% (9)58.33% (7)0.72
 Rheumatic heart disease20% (6)27.78% (5)8.33% (1)0.36
Active smoking16.6% (5)11.1% (2)25% (3)0.364
Previous myocardial infarction3.33% (1)08.33% (1)0.4
History of thrombotic event3.33% (1)08.33% (1)0.4
Abdominal pain (%/)96.67% (29)94.44% (17)100% (12)1.0
Nausea (%/)76.7% (23)88.89% (16)58.3% (7)0.08
Emesis (%/)46.67% (14)55.55% (10)33.33% (4)0.28
Bloating (%/)60% (18)61.11% (11)58.33% (7)1.0
Bloody diarrhea (%/)40% (12)55.55% (10)16.67% (2)0.06
Intestinal obstruction (%/)20% (5)11.11% (2)25% (3)0.36
WBC count (103/dL)0.1981.3
Blood urea nitrogen (IQR) (mg/dL)7.2 (5.3–8.7)7.1 (5.7–8.6)8.0 (5.0–8.8)0.820.23
Creatinine (mg/dL)0.6610.44
Potassium (mg/dL)0.490.7
pH0.5120.67
Aspartate transaminase (IQR) (U/L)30 (19.0–45.3)32.5 (20–51)28 (18.3–42.5)0.7850.28
Alanine transaminase (IQR) (U/L)20.5 (15.5–44)21.5 (18.5–4.8)20 (11–39)0.261.2
Lactate (IQR) (mmol/L)2.6 (1.6–3.7)2.0 (1.3–3.3)3.0 (2.0–4.0)0.3470.96
Maxim lactate (IQR) (mmol/L)2.6 (2.0–4.0)2.3 (1.7–3.3)3.5 (2.0–4.8)0.1251.6
D-dimer (mg/L)0.8310.22
Fibrinogen (g/L)0.0532.02

WBC, white blood cell; IQR, Interquartile range; denotes comparisons between endovascular therapy and open surgical therapy.